Cargando…

Significance of T-Cell Subsets for Clinical Response to Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B Patients

INTRODUCTION: The adaptive immune response may reflect the immunomodulatory efficacy during peginterferon alfa-2a (PEG-IFN α-2a) treatment in chronic hepatitis B (CHB) patients. We evaluated the predictive efficiency of T-cell subsets on patient’s response to PEG-IFN α-2a treatment. METHODS: The pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Li, Li, Jin, Xu, Junchi, Chen, Fan, Wu, Xunxun, Zhu, Chuanwu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058244/ https://www.ncbi.nlm.nih.gov/pubmed/35509606 http://dx.doi.org/10.2147/IJGM.S356696

Ejemplares similares

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients
por: Yang, Song, et al.
Publicado: (2016)

Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a
por: Jia, Wen, et al.
Publicado: (2019)

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B
por: Wei, Lai, et al.
Publicado: (2018)

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B
por: van Campenhout, Margo J. H., et al.
Publicado: (2020)

Role of interleukin-21 and interleukin-21 receptor polymorphisms in the treatment of HBeAg-positive chronic hepatitis B patients with peginterferon
por: Wang, Xia, et al.
Publicado: (2018)

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients
por: Yang, Jiezuan, et al.
Publicado: (2014)

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B
por: Winther, Thilde Nordmann, et al.
Publicado: (2013)

Efficacy of Peginterferon alfa-2b in Nucleoside Analogue Experienced Patients with Negative HBeAg and Low HBsAg: A Non-Randomized Clinical Trial
por: Chen, Jun, et al.
Publicado: (2021)

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
por: Song, Guangjun, et al.
Publicado: (2023)

CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study
por: Zhang, Ka, et al.
Publicado: (2016)

HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B
por: Zhang, Chong, et al.
Publicado: (2020)

The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore
por: Lacey, L F, et al.
Publicado: (2007)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Analysis of clinical and virologic features in Hepatitis B e Antigen (HbeAg)-negative and HbeAg-positive Egyptian chronic hepatitis B patients
por: Fouad, Rabab, et al.
Publicado: (2020)

Impact of Drug-Resistance Polymerase Mutations on the Replication of HBeAg-Positive and HBeAg-Negative Hepatitis B Virus Strains in Vitro
por: Tacke, Frank, et al.
Publicado: (2012)

Manifestations of Perihepatic Lymph Nodes in Acute Flare of Chronic Hepatitis B: Association with HBeAg Status and with HBeAg Seroconversion
por: Ko, Yen-Ling, et al.
Publicado: (2015)

Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon
por: Hou, Feng-Qin, et al.
Publicado: (2015)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
por: Lim, Chee Kent, et al.
Publicado: (2006)

Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China
por: Chen, Tianyan, et al.
Publicado: (2018)

Performance of Hepatitis B Core-Related Antigen Versus Hepatitis B Surface Antigen and Hepatitis B Virus DNA in Predicting HBeAg-positive and HBeAg-negative Chronic Hepatitis
por: Zhang, Zhan-qing, et al.
Publicado: (2019)

Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection
por: Zhang, Zhanqing, et al.
Publicado: (2021)

Efficacy of peginterferon α-2a and predictors of response in HBeAg-negative, genotype D-naive patients
por: Al-Ashgar, Hamad I., et al.
Publicado: (2011)

HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History
por: Bonino, Ferruccio, et al.
Publicado: (2022)

Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study
por: Yang, Xiaoling, et al.
Publicado: (2017)

Is the function of the HBeAg really unknown?
por: Milich, David R.
Publicado: (2019)

Dynamic Changes of Cytokine Profiles and Virological Markers Associated With HBsAg Loss During Peginterferon Alpha-2a Treatment in HBeAg-Positive Chronic Hepatitis B Patients
por: Li, Minghui, et al.
Publicado: (2022)

Elevated serum levels of soluble CD14 in HBeAg‐positive chronic HBV patients upon Peginterferon treatment are associated with treatment response
por: Dou, Yingying, et al.
Publicado: (2019)

Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients
por: Zhao, Jing, et al.
Publicado: (2023)

Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B
por: Zhu, Xiao-Feng, et al.
Publicado: (2011)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
por: Ma, Hui, et al.
Publicado: (2016)

Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B
por: Dimzova, Marija, et al.
Publicado: (2019)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
por: Song, Byung-Cheol, et al.
Publicado: (2014)

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis
por: Xing, Tongjing, et al.
Publicado: (2017)

A cautionary note to hepatitis B e antigen (HBeAg)‐negative test results in pregnant women in an area prevalent of HBeAg‐negative chronic hepatitis B
por: Chalid, Maisuri T., et al.
Publicado: (2022)

Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B
por: Xiong, Yue-Li, et al.
Publicado: (2016)

Effect of Adenine Arabinoside and α-Interferon in Patients with HBeAg-positive Chronic Active Hepatitis
por: Lee, Sang Uk, et al.
Publicado: (1990)

Prevalent HBeAg-negative HBV DNA-positive Chronic Hepatitis B Individuals in Bangladesh
por: Rashed Ul Islam, SM, et al.
Publicado: (2021)

The Effectiveness of Antiviral Treatments for Patients with HBeAg-Positive Chronic Hepatitis B: A Bayesian Network Analysis
por: Hao, Zhang, et al.
Publicado: (2018)

qHBsAg for the Identification of Liver Histological Abnormalities in HBeAg-Negative Chronic Hepatitis B Patients with Normal and Mildly Elevated ALT Levels
por: Gan, Qinyi, et al.
Publicado: (2022)

Study on Post-Treatment Relapse in HBeAg Positive CHB Patients
por: Lu, Junfeng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1ak9msm30kv1ns2ql1m2tg0mt7